Biomerica vs Anbio Biotechnology
BMRA and NNNN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BMRA and NNNN compare
Anbio Biotechnology grew revenue faster over the last twelve months (5.6% versus −11.2% for Biomerica).
Anbio Biotechnology keeps more of each dollar of sales as profit, with a net margin of 74.1% compared with −115% at Biomerica.
Anbio Biotechnology scores higher on the StockData Score (11 against 8 for Biomerica), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BMRA | NNNN |
|---|---|---|
| Size and price | ||
| Market cap | $6.3M | – |
| Share price | $1.36 | $3.82 |
| Change, 1 year | −46.0% | −83.0% |
| Change, 5 years | −96.7% | – |
| Beta (5Y) | 0.96 | 1.55 |
| Employees | 17 | 27 |
| StockData Score | ||
| Total score | 8 | 11 (better) |
| Valuation score | 3 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 5 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.4× | – |
| P/B | 1.7× | – |
| Fair value | $2.35 | – |
| Margin of safety | 42.2% | – |
| Growth | ||
| Revenue growth (TTM) | −11.2% | 5.6% (better) |
| Revenue growth, 5Y average | −9.2% | – |
| Net income growth (TTM) | – | 170% |
| EPS growth (TTM) | – | 163% |
| Profitability | ||
| Gross margin | 0.90% | 87.2% (better) |
| Operating margin | −125% | 66.7% (better) |
| Net margin | −115% | 74.1% (better) |
| Return on equity | −114% | 27.0% (better) |
| Return on invested capital | −284% | 48.7% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 1.91 | 344.31 (better) |
| Altman Z-score | −10.54 | – |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | −50.6% | – |
| Shareholder yield | −50.6% | – |
| Ownership | ||
| Held by institutions | 2.7% | – |
| Held by insiders | 27.4% | 0.00% |
| Insider net buying, 12 months | $158K | – |
| Short interest, % of float | 0.37% | 0.02% |
Go deeper
- BMRA stock overview
- BMRA income statement
- BMRA valuation and score
- NNNN stock overview
- NNNN income statement
- NNNN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.